Pfenex Inc (PFNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The companys lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple sclerosis; PF708, a peptide product candidate to treat high-risk fracture patients; and others. Pfenexs preclinical products under development include PF529, a biosimilar candidate to neulasta; PF688, a biosimilar candidate to cimzia, PF444, PF690; and others. The company produces biosimilar product with protein production platform and bioanalytic approach. It partners with the US government for developing vaccines for anthrax and malaria. Pfenex is headquartered in San Diego, California, the US.

Pfenex Inc (PFNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pfenex Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Pfenex Enters into Research Agreement with Path Vaccine Solutions 11
Pfenex Forms Joint Venture With Agila Biotech 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Pfenex Enters Into Co-Development Agreement With ProZyme 14
Licensing Agreements 15
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15
Pfenex Enters into Licensing Agreement with China NT Pharma Group 16
Jazz Pharma Amends Licensing Agreement with Pfenex 17
Nemucore Medical Enters into Licensing Agreement with Pfenex 19
Equity Offering 20
Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20
Pfenex Raises USD43 Million in Public Offering of Shares 21
Pfenex Raises USD40.4 Million in Public Offering of Shares 23
Pfenex Raises USD50 Million in IPO 25
Pfenex Inc - Key Competitors 26
Pfenex Inc - Key Employees 27
Pfenex Inc - Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
May 10, 2018: Pfenex Reports First Quarter 2018 Results and Provides Business Update 29
Mar 15, 2018: Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update 31
Nov 09, 2017: Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update 33
Aug 09, 2017: Pfenex Reports Second Quarter 2017 Results and Provides Business Update 35
May 08, 2017: Pfenex Reports First Quarter 2017 Results and Provides Business Update 37
Mar 15, 2017: Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update 39
Corporate Communications 41
Aug 16, 2018: Pfenex announces departure of chief medical and scientific officer Dr. Hubert Chen 41
Jan 04, 2018: Pfenex Names Susan A. Knudson as CFO 42
Sep 07, 2017: Pfenex Announces Management Changes 43
Aug 03, 2017: Pfenex Names Eef Schimmelpennink Chief Executive Officer 44
Apr 03, 2017: Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors 45
Mar 31, 2017: William R. Rohn Announces Plans To Retire As Chairman And Board Member 46
Jan 24, 2017: Pfenex Announces Leadership Transition 47
Product Approvals 48
May 14, 2018: Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables


Pfenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pfenex Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pfenex Enters into Research Agreement with Path Vaccine Solutions 11
Pfenex Forms Joint Venture With Agila Biotech 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Pfenex Enters Into Co-Development Agreement With ProZyme 14
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15
Pfenex Enters into Licensing Agreement with China NT Pharma Group 16
Jazz Pharma Amends Licensing Agreement with Pfenex 17
Nemucore Medical Enters into Licensing Agreement with Pfenex 19
Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20
Pfenex Raises USD43 Million in Public Offering of Shares 21
Pfenex Raises USD40.4 Million in Public Offering of Shares 23
Pfenex Raises USD50 Million in IPO 25
Pfenex Inc, Key Competitors 26
Pfenex Inc, Key Employees 27

List Of Figures


Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pfenex Inc (PFNX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The companys lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases.

USD 250 View Report

Pfenex Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Pfenex Inc Company Profile is a detailed strategic and analytical report on Pfenex Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Pfenex Inc (PFNX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The companys lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases.

USD 250 View Report

Pfenex Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Pfenex Inc Company Profile is a detailed strategic and analytical report on Pfenex Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available